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Abstract
Purpose Synthetic cannabinoids (SCs) represent a large proportion of novel psychoactive substances on the black market 
and have caused a number of deaths. Polydrug use including combination of SCs and ethanol could further complicate the 
toxicological impact. To the best of our knowledge, there have been no reports presenting evidence of transesterification 
between SCs and ethanol in vitro.
Methods The in vitro metabolism of the four carboxylate SCs PB-22, NPB-22, 5-fluoro-PB-22 (5F-PB-22), and 5-fluoro-
NPB-22 (5F-NPB-22) in the presence of ethanol using human liver microsomes with and without appropriate enzyme inhibi-
tors was studied. Newly identified SC ethyl esters were chemically synthesised and fully characterised. The activity of these 
SCs and their ethanol transesterification products were assessed using cannabinoid receptor  (CB1 and  CB2) activation assays.
Results SCs/ethanol transesterification products were detected and studied using liquid chromatography–high-resolution 
mass spectrometry. We have shown that the SC ethyl ester formation is mediated by human carboxyl esterase enzymes. The 
ethyl esters exhibited a reduced activity for the CB receptors compared with their parent compounds.
Conclusions These novel ethyl esters may be useful additional markers of cannabinoid administration, and especially so if 
they prove to have longer half-lives than their parent compounds.
Keywords Carboxylate synthetic cannabinoids · In vitro drug metabolism · Transesterification · 5F-NPB-22 · Ethanol · 
Biomarkers
Introduction
The use of synthetic cannabinoid receptor agonists, or sim-
ply ‘synthetic cannabinoids’ (SCs), is a global toxicologi-
cal conundrum. Their use appears to have escalated during 
2008–2015 [1] under the pretence that these compounds are 
‘safe’ and ‘legal’ [2], and it is assumed that their use cannot 
easily be detected [3]. Although there has been a decline 
in seized SCs recently, many of the recent substances are 
highly potent and harmful [1]. Originally, these compounds, 
which circumvented drug legislation in many countries, 
were sold over-the-counter in so-called headshops and on 
the Internet as vividly branded products such as ‘Spice’ in Electronic supplementary material The online version of this article (https ://doi.org/10.1007/s1141 9-019-00491 -0) contains 
supplementary material, which is available to authorized users.
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Europe and ‘K2’ in the United States. The weakness of the 
Misuse of Drugs Act [4] and incorporated schedules in the 
UK could not readily keep up with the rapidity of novel 
compounds reaching the market, but the more recent UK 
Psychoactive Substances Act (PSA) in 2016 [5] appears to 
be having an impact. While some data suggest that the use 
of novel psychoactive substances (NPS), including SCs, has 
decreased since the introduction of the PSA, other studies 
suggest little impact in the number of emergency department 
presentations, and their use remains prevalent and problem-
atic [6]. As of the end of 2017, more than 670 NPS were 
monitored by the European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA), and 179 out of these were 
SCs [1]. In the UK, this is especially relevant in the prisoner 
population and amongst those facing homelessness [3, 7]. 
Not only are the clinical features of acute SC toxicity dif-
ficult to identify and treat, particularly for the more recent 
third-generation SCs [6, 8, 9], but the analysis of these com-
pounds in bulk-drug seizures and in biological samples can 
also be challenging, even using the most modern analytical 
instrumentation. Analysis is complicated by (1) the sheer 
number of SCs that exist [10, 11], (2) their physicochemical 
diversity, (3) the frequent formation of multiple (pharmaco-
logically active) metabolites [10, 12–14], (4) their (in)stabil-
ity and chemical transformations when ingested via smoking 
(i.e., their pyrolysis products [15–18]), (5) their potency, 
which transpires to low concentrations in biological samples, 
and (6) the limited availability of reference materials. To 
aid the identification of SCs and their metabolites, in vitro 
models based on incubation with human liver microsomes 
(HLMs) and other enzyme fractions [19], coupled with in 
silico predictions, are commonly used to determine the most 
likely metabolic routes of ‘new’ SCs [20]. In silico models 
are also extremely useful at predicting the pharmacology 
and potential toxicology of SCs [21, 22]. Such literature 
resources are invaluable for building large screening librar-
ies to maximise the chances of detecting toxicologically 
relevant SC use in samples.
However, in substance-using populations, polydrug use is 
common [23]. Considerations of drug-drug interactions with 
SCs are important clinically [24], but possible or unexpected 
biotransformation due to co-ingested compounds should also 
be considered. For example, transesterification of cocaine 
following concomitant use of ethanol and cocaine is well 
known to produce the pharmacologically active metabolite 
cocaethylene [25, 26]. Similarly, transesterification has also 
been demonstrated for methylphenidate, resulting in the pro-
duction of ethylphenidate (itself an NPS with misuse poten-
tial) [27]. These reactions are primarily catalysed by human 
carboxylesterases (hCES) in the liver, which participate in 
phase I metabolism of xenobiotics. Transesterification of 
PB-22 can also be observed as a thermal degradation artefact 
when detecting by gas chromatography–mass spectrometry 
(GC–MS) in the presence of methanol or ethanol as a sol-
vent [28].
There is increasing evidence confirming the use of SCs 
together with ethanol. A recent United Nations Office on 
Drugs and Crime (UNODC) report [29] highlighted ethanol 
as the third most frequent substance found in SC-related 
fatalities. In addition, ester-based SCs including 5F-PB-22 
were detected, together with ethanol and other substances in 
postmortem cases [30, 31]. ADB-CHMINACA (also known 
as MAB-CHMINACA) and ethanol were both detected in 
a patient admitted to hospit [32]. A further case reported a 
fatal poisoning with the synthetic cannabinoid AB-CHMI-
NACA and ethanol [33]. Finally, blood and urine ethanol 
concentrations were reported in three fatalities related to 
the use of 5F-ADB, 5F-PB-22 and AB-CHMINACA (5F-
PB-22 = 2.60 and 3.58 g/kg, AB-CHMINACA = 1.45 and 
2.57 g/kg, 5F-ADB = 0.09 and 0.12 g/kg for blood and urine 
ethanol concentrations, respectively) [34]. It is apparent that 
the discovery of novel biomarkers of concomitant SC-etha-
nol consumption should facilitate the interpretation of such 
analytical investigations and may allow both extending the 
detection time and assisting in the understanding of the pat-
terns of toxicity associated with such polydrug abuse.
In this study, we report in vitro evidence from HLM incu-
bation experiments for the transesterification of four ester-
containing SCs, namely PB-22, NPB-22, 5F-PB-22, and 
5F-NPB-22 (Fig. 1), in the presence of ethanol, giving rise 
to a further group of potential new indicators of combined 
SC/ethanol use. These compounds were chosen because of 
the presence of a labile ester bond in their structures, making 
them amenable to the described chemical reaction, as well 
as their prevalence [35].
To evaluate whether the transesterification products might 
be more biologically active than the parent compounds, we 
used an activity-based cannabinoid receptor assay [36–38] 
to investigate the in vitro receptor activity of the ethyl esters 
formed by transesterification of ethanol with these SCs.
Materials and methods
Chemicals and reagents
PB-22, NPB-22, 5F-PB-22 and 5F-NPB-22 were kindly pro-
vided by TICTAC Communications (London, UK). Their 
identity and purity were confirmed by nuclear magnetic 
resonance (NMR) spectroscopy and high-performance liq-
uid chromatography–ultraviolet spectroscopy (HPLC–UV) 
(% purity > 90%). Methanol, acetonitrile, formic acid (all 
LC–MS grade) were purchased from Fisher Scientific 
(Loughborough, UK). Trifluoroacetic acid (TFA), chloro-
form-d  (CDCl3, isotopic purity 99.8 atom  %D) were from 
Sigma-Aldrich (Dorset, UK). Deionised water was purified 
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to 18.2 MΩ cm resistivity using a PURELAB Ultra sys-
tem (ELGA, Woodridge, UK). Aqueous phosphate buffer 
(0.5  mol/L, pH 7.4), pooled HLMs (150 donors), and 
reduced nicotinamide adenine dinucleotide phosphate 
(NADPH) regenerating system solutions A and B were pur-
chased from Corning (Woburn, MA, USA); ethyl indazole-
3-carboxylate and 1-bromo-5-fluoropentane from Fluoro-
Chem (Hadfield, UK); 1,5-diiodopentane from Alfa Aesar 
(Lancashire, UK); ethyl indole-3-carboxylate and potas-
sium tert-butoxide (tBuOK) from Aldrich (Dorset, UK); 
potassium hydroxide (KOH), bis-p-nitrophenylphosphate 
(BNPP), tetrahydrofuran (THF), hexane, ethyl acetate and 
ethanol from Sigma-Aldrich (St. Louis, MO, USA); anhy-
drous THF from Acros Organics (Geel, Belgium).
Synthesis and characterisation of ethyl esters
Synthesis of the ethyl esters (compounds 10, 11, 14 and 
15, Fig. 1) was carried out via nucleophilic substitutions of 
the N1 nitrogen atoms of (1) ethyl indazole-3-carboxylate 
and (2) ethyl indole-3-carboxylate, each with 1,5-diiodo-
pentane and 1-bromo-5-fluoropentane, to form the non-
fluorinated and fluorinated analytes, respectively. Ester 
hydrolysis products (compounds 12, 13, 16 and 17, Fig. 1) 
were synthesised by alkaline hydrolysis of ethyl esters. 
Summary experimental data are given in supplementary 
material section S1. Ethyl esters were characterised using 
NMR (1H-NMR, 13C-NMR, homonuclear correlation 
spectroscopy—COSY, and heteronuclear single-quantum 
correlation spectroscopy—HSQC) (NMR, Bruker Avance 
DRX 400 MHz; Bruker BioSpin, Rheinstetten, Germany).
Further analysis was carried out using reversed-phase 
high-performance liquid chromatography with diode-array 
detection (HPLC–DAD, HP-1050) (Agilent Technologies, 
Santa Clara, CA, USA) using a 100 × 2.1 mm i.d. C8 column 
(5 µm,  Kinetex®; Phenomenex, Torrance, CA, USA). Solu-
tions of each compound [100 μg/mL in 0.1% (v/v) TFA in 
water] were eluted using a water/acetonitrile gradient (both 
containing 0.1% (v/v) TFA, ambient temperature, 31 min 
analysis time). Finally, solutions of each compound [300 ng/
mL in 10% (v/v) acetonitrile in deionised water containing 
0.3% (v/v) formic acid] were analysed by liquid chromatog-
raphy–high-resolution mass spectrometry (LC–HRMS) to 
generate reference retention times and product ion  (MS2) 
spectra for the in vitro incubation experiments.
Fig. 1  Chemical structures of 
5F-NPB-22, NPB-22, PB-22 
and 5F-PB-22 (top panel), their 
corresponding ethyl esters (mid-
dle panel) and their hydrolysis 
product (bottom panel). SCs 
synthetic cannabinoids
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In vitro incubation
The HLM method was based on that previously described 
[19]. Briefly, solutions containing 10 µg of each substrate 
(1 mg/mL, 10 µL) were added to Eppendorf LoBind™ 
tubes (Stevenage, UK), and evaporated to dryness. Buffer 
solution (0.1  mol/L aqueous phosphate buffer, pH 7.4, 
500 µL), NADPH-regenerating solutions [50 µL solution 
A: 26 mmol/L  NADP+, 66 mmol/L glucose-6-phosphate, 
and 66 mmol/L  MgCl2 (aq); 10 µL solution B: 40 U/mL 
glucose-6-phosphate dehydrogenase in 5 mmol/L sodium 
citrate], and deionised water (390 µL) were added. The tubes 
were capped, vortex-mixed, and preincubated (37 °C) with 
continuous gentle shaking for 10 min using an Eppendorf 
 ThermoMixer® (Stevenage, UK). Reactions were initiated 
by the addition of HLM solution [protein content 20 mg/mL 
in 250 mmol/L sucrose (aq), 50 µL], gently mixed by hand 
and were incubated using an Eppendorf  ThermoMixer® (2 h, 
total reaction volume 1000 µL). A negative control was pre-
pared by incubating each of the compounds with buffer solu-
tion and water, omitting the HLM and NADPH solutions. 
For incubations with ethanol, the initial volume of deionised 
water added to the incubation mixture was reduced to 340 
µL, and aqueous ethanol solution [5.86% (v/v), 50 µL] was 
added. The final concentration of ethanol was 50 mmol/L 
(0.23 g/dL). In addition, incubations were carried out in the 
presence of specific carboxylesterase (CES), and nonspe-
cific esterase inhibitors (BNPP and saturated NaF solution, 
respectively). For both experiments, the initial volume of 
deionised water added to the incubation mixture was reduced 
to 290 µL, and aqueous ethanol solution [5.86% (v/v), 50 µL] 
and inhibitor solution [either 1 mmol/L BNPP, or 10% (w/v) 
NaF in water, 50 μL] was added. The final concentration of 
ethanol was maintained at 50 mmol/L.
After incubation, all reactions were quenched by the 
addition of ice-cold acetonitrile (250 μL). Quenched solu-
tions were vortex-mixed and centrifuged (13,000 g, 15 min). 
Supernatants were transferred to glass autosampler vials for 
analysis by LC–HRMS (5 μL injection volume).
LC–HRMS
An UltiMate 3000™ HPLC system coupled to a Q 
Exactive™ high-resolution mass spectrometer (both Thermo 
Scientific, San Jose, CA, USA) was used. Xcalibur™ soft-
ware (version 14.0) was used for instrument control and 
data analysis. Chromatographic separation was performed 
using an Acquity™ BEH C18 column (50 × 2.1 mm i.d., 
1.7 μm) (Waters, Borehamwood, UK). Eluents consisted of 
0.3% (v/v) formic acid in deionised water (eluent A) and 
in acetonitrile (eluent B). Column temperature was main-
tained at 40 °C. The elution gradient started at 10% eluent 
B (2 min), ramped to 95% (over 5 min), and then decreased 
immediately to 10% (over 1 min) prior to re-equilibration. 
The total analysis time was 10 min.
Heated electrospray ionisation (HESI-II) settings were: 
sheath gas flow-rate 70; auxiliary gas flow-rate 10; spray 
voltage 3.75 kV; capillary temperature 320 °C; S-lens radio 
frequency level 55.0; auxiliary gas temperature 350 °C. Full-
scan acquisition parameters were: positive ionisation mode; 
scan range m/z 100–1000; resolution 70,000 full width at 
half maximum (FWHM); automatic gain control (AGC) tar-
get 1 × 106.  MS2 acquisition parameters were: parallel reac-
tion monitoring mode (based on an inclusion list containing 
the appropriate precursor ions); scan range m/z 100–750; 
resolution 35,000 FWHM; AGC target 1 × 106. The isola-
tion width was 1.2 amu. The normalised collision energy 
(NCE) was optimised manually using available standards 
and in-house synthesised products. For data review, total ion 
chromatograms were extracted using a ± 2.5 ppm extraction 
window based on the exact m/z values.
Cannabinoid receptor assay
To assess the biological activities of the compounds, live 
cell-based reporter assays that monitor protein-protein inter-
actions via the NanoLuc Binary Technology were used. 
Here, the receptor activation is evaluated via the interac-
tion between β-arrestin 2 (βarr2), a cytosolic protein, and 
the cannabinoid receptor  CB1 or  CB2. Both βarr2 and  CB1/
CB2 are fused to an inactive part of nanoluciferase. When 
 CB1 or  CB2 are activated by a ligand, βarr2 is recruited to 
the receptor, allowing interaction of the complementary 
nanoluciferase subunits, yielding a functional enzyme that 
generates a bioluminescent signal in the presence of the sub-
strate furimazine. Details regarding the development of the 
stable  CB1 and  CB2 cell lines used here have been reported 
elsewhere [36]. The original human embryonic kidney 
(HEK) T293 cell line was provided by Prof. O. De Wever 
(Laboratory of Experimental Cancer Research, Department 
of Radiation Oncology and Experimental Cancer Research, 
Ghent University Hospital, Belgium).
The cells were routinely maintained at 37 °C, 5%  CO2, 
under humidified atmosphere in Dulbecco’s modified Eagle’s 
medium (GlutaMAX™; Thermo Fisher Scientific, Waltham, 
MA, USA) supplemented with 10% heat-inactivated fetal 
bovine serum (FBS), 100 IU/mL penicillin, 100 mg/L strep-
tomycin and 0.25 mg/L amphotericin B. Stability of the cell 
lines was followed by flow cytometric analysis. For experi-
ments, cells were deposited on poly-d-lysine coated 96-well 
plates (Thermo Fisher Scientific) at 5 ×  104 cells/well and 
incubated overnight. The cells were washed twice with Opti-
MEM® I Reduced Serum Medium (Thermo Fisher Scien-
tific) to remove any remaining FBS, and 100 μL Opti-MEM® 
I was added. The Nano-Glo Live Cell reagent (Promega, 
Madison, WI, USA), a nonlytic detection reagent containing 
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the cell permeable furimazine substrate, was prepared by 
20-fold dilution of the Nano-Glo Live Cell substrate using 
Nano-Glo LCS Dilution buffer, and 25 μL were added to 
each well. Subsequently, the plate was placed into a  TriStar2 
LB 942 multimode microplate reader (Berthold Technolo-
gies GmbH & Co., Bad Wildbad, Germany). Luminescence 
was monitored during the equilibration period until the sig-
nal stabilised (15 min). We added 10 μL per well of test 
compounds, present as concentrated (13.5-fold) stock solu-
tions in 50% (v/v) methanol in Opti-MEM® I. The lumi-
nescence was continuously detected for 120 min. Solvent 
controls were analysed with all experiments. The final con-
centration of methanol (3.7% v/v) has previously been veri-
fied to be well-tolerated by the cells [36].
Curve fitting and statistical analyses were performed 
using GraphPad Prism software (San Diego, CA, USA). 
The results are represented as mean area under the curve 
(AUC) ± standard deviation (SD) with at least five replicates 
for each data point (obtained in three independent experi-
ments). All results were normalised to the Emax of JWH-018 
(= 100%), our reference compound. Curve fitting of concen-
tration-effect curves via nonlinear regression (four param-
eters logistic fit) was employed to determine  EC50 (a meas-
ure of potency) and the Emax (a measure of efficacy). The 
maximal effect of all compounds was determined by either 
the Emax (for the parent compounds) or the maximal effect 
that was achieved for the compound at high concentrations.
Results and discussion
Characterisation of compounds
Data from the characterisation experiments (NMR and 
HPLC–UV) for the synthesised compounds (10-17) are 
presented in supplementary material section S1. Reten-
tion times, precursor ion m/z values (all [M+H]+), and 
major product ion m/z values for the parent compounds 
and the eight synthesised compounds generated using the 
LC–HRMS method are summarised in Table 1.
For the indoles PB-22 and 5F-PB-22, the characteristic 
major product ions observed were in agreement with previ-
ously published data [39], resulting from successive losses 
of the hydroxyquinolinyl substructures (m/z 214.1228 and 
232.1121 for PB-22 and 5F-PB-22, respectively) and the 
(fluoro-) alkyl chains (m/z 144.0445 and 144.0435 for both 
compounds).
Product ions spectra for the two indazoles, NPB-22 and 
5F-NPB-22, showed analogous product ions (m/z 215.1183 
and 233.1074 for NPB-22 and 5F-NPB-22, respectively, 
plus 145.0398 and 145.0389 for both compounds). In 
addition, the indazoles gave rise to fragment ions corre-
sponding to losses of the quinolinyl substructures, i.e., 
of the same m/z as the precursor ions for compounds 13 
and 12, the ester hydrolysis products (m/z 233.1288 and 
Table 1  Summary LC–HRMS data for parent and synthesised compounds PB-22, NPB-22, 5F-PB-22, 5F-NPB-22, and metabolites 10-17 
 LC–HRMS liquid chromatography–high-resolution mass spectrometry, RT retention time
Compound (formula) RT (min) Precursor ion 
accurate m/z (Δ 
ppm)
Major product ion(s) accurate m/z (Δ ppm)
PB-22  (C23H22N2O2) 6.21 359.1759 (1.39) 214.1228 (0.93), 144.0445 (0.69)
NPB-22  (C22H21N3O2) 6.29 360.1714 (1.94) 233.1288 (1.29), 215.1183 (1.86), 145.0398 (1.38)
5F-PB-22  (C23H21N2O2F) 6.05 377.1652 (−2.12) 232.1121 (−4.74), 144.0435 (−6.25)
5F-NPB-22  (C22H20N3O2F) 6.03 378.1603 (−2.38) 251.1178 (−4.78), 233.1074 (−4.72), 213.1015 (−3.28), 
145.0389 (−4.83)
PB-22 ethyl ester (15)  (C16H21NO2) 6.52 260.1651 (2.31) 232.1336 (1.72), 214.1231 (2.34), 188.1439 (2.66), 
132.0811 (2.27), 118.0654 (2.54)
NPB-22 ethyl ester (11)  (C15H20N2O2) 6.34 261.1598 (0.00) 233.1282 (−1.29), 215.1178 (−0.46), 145.0395 (−0.70)
5F-PB-22 ethyl ester (14)  (C16H20NO2F) 5.98 278.1556 (1.80) 250.1241 (1.20), 232.1136 (1.72), 206.1345 (2.43), 
132.0811 (2.27)
5F-NPB-22 ethyl ester (10)  (C15H19N2O2F) 5.82 279.1503 (0.00) 251.1188 (−0.80), 233.1083 (−0.86), 213.1021 (−0.47), 
145.0396 (0.00)
PB-22 ester hydrolysis product (17)  (C14H17NO2) 5.61 232.1334 (0.86) 214.1225 (−0.47), 188.1433 (−0.53), 132.0807 (−0.76), 
118.0651 (0.00)
NPB-22 ester hydrolysis product (13)  (C13H16N2O2) 5.21 233.1291 (2.57) 215.1183 (1.86), 163.0505 (1.84), 145.0399 (2.07)
5F-PB-22 ester hydrolysis product (16)  (C14H16NO2F) 5.03 250.1244 (2.40) 232.1135 (1.29), 206.1344 (1.94), 132.0811 (2.27)
5F-NPB-22 ester hydrolysis product (12) 
 (C13H15N2O2F)
4.85 251.1192 (2.80) 233.1084 (−0.43), 213.1022 (0.00), 145.0397 (0.69)
5F-NPB-22 methyl ester  (C14H17N2O2F) 5.48 265.1354 (2.64) 251.1195 (1.99), 233.1089 (1.72), 213.1029 (3.28)
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251.1178 for NPB-22 and 5F-NPB-22, respectively). For 
5F-NPB-22, a defluorinated product ion was also observed 
(m/z 213.1015) which was not observed in the case of 
5F-PB-22.
For the ethyl ester and ester hydrolysis products of 
PB-22 (compounds 15 and 17), the major protonated car-
bonyl-indole core fragment ion (m/z 144.0444) was not 
observed at any significant relative abundance. Instead, 
the proposed alkyl-indole and alkyl-indole carboxylic acid 
product ions (m/z 188.1439 and 232.1336, respectively) 
were the major product ions for PB-22 ethyl ester, com-
pound 15 (Fig. 2), in addition to a small amount of the ion 
at m/z 214.1231 also observed for both compounds 15 and 
17. The ethyl ester of PB-22 gave rise to a product ion at 
m/z 132.0811 and 118.0654, which were observed as major 
product ions of PB-22 ester hydrolysis, compound 17.
With respect to the ethyl esters and hydrolysis products 
of 5F-PB-22 (compounds 14 and 16), similar fragments as 
PB-22 ethyl ester and ester hydrolysis were observed. The 
major product ions were the alkyl-indole, m/z 206.1337; 
and product ions at m/z 250.1234, 232.1129 and 118.0650 
being the fragments of alkyl-indole carboxylic acid, alkyl-
indole carbaldehyde and indole group, respectively. The 
ethyl ester of 5F-PB-22 also gave rise to a product ion at 
m/z 132.0806.
Observed product ions of NPB-22 ethyl ester and 
5F-NPB-22 ethyl ester included the alkyl-indazole carbox-
ylic acid, alkyl-indazole carbaldehyde, and indazole car-
baldehyde (m/z 233.1276, 215.1171, and 145.0391 for NPB-
22, m/z 251.1187, 233.1082, and 145.0395 for 5F-NPB-22, 
respectively). The 5F-NPB-22 ethyl ester also yielded a 
defluorinated fragment (m/z 213.1020) (Fig. 3) as observed 
in  MS2 result of 5F-NPB-22 parent compound. The ester 
hydrolysis product ions of NPB-22 and 5F-NPB-22 gave 
similar results to those of their corresponding ethyl esters.
HLM incubation experiments
PB‑22 and 5F‑PB‑22
In the absence of ethanol, metabolism of PB-22 proceeded 
as previously described to produce a series of phase I 
metabolites [39]. The major metabolite (by relative abun-
dance) was the ester hydrolysis product (compound 17). 
Of note, this compound was also observed at a lower 
abundance (approximately 1% of the parent compound) 
in the negative control samples, in which no HLMs were 
included in the incubation (see supplementary material 
S3.4). In addition to the ester hydrolysis product, a series 
of hydroxylated metabolites were observed, with charac-
teristic  MS2 fragments suggesting monohydroxylation on 
(1) the pentyl chain, (2) the indole core and (3) the quin-
olinyl substructure, carbonylation of the pentyl chain, and 
successive hydroxylation products following ester hydroly-
sis and N-dealkylation. When ethanol was present, in addi-
tion to these metabolites, the previously synthesised and 
characterised PB-22 ethyl ester was also detected along 
with further peaks suggesting monohydroxylation of the 
ethyl ester (Fig. 4). No ethyl ester was observed when 
PB-22 was incubated with ethanol in the presence of either 
saturated NaF (nonspecific CES inhibitor) or 1 mmol/L 
BNPP (specific CES inhibitor) (see supplementary mate-
rial S3.2-S3.3). The observed LC–HRMS analyses and the 
 MS2 spectra of ethyl esters when SCs were incubated with 
HLM and ethanol matched with the synthetic standards 
(see supplementary material S2.1-2.8 and S1.28-1.35). 
Fig. 2  Product ion  (MS2) spec-
trum (annotated with proposed 
fragment ion structures) for the 
ethyl ester of PB-22 (compound 
15, exact m/z for protonated 
molecular ion 260.1645) with 
normalised collision energy 
(NCE) at 25
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A summary of the observed in vitro phase I metabolism, 
including transesterification in the presence of ethanol, for 
PB-22 is shown in Fig. 5.
For the fluorinated indole analogue 5F-PB-22, oxida-
tive, reductive defluorination and oxidative defluorination 
to carboxylic acid products (see supplementary material 
S3.8) were observed in addition to the metabolites seen for 
PB-22. In the presence of ethanol, and ethanol plus CES-
inhibitor, similar results to its non-fluorinated analogue were 
observed.
These data demonstrate for the first-time evi-
dence of hCES-mediated transesterification of selected 
Fig. 3  MS2 spectrum (annotated 
with proposed fragment ion 
structures) for the ethyl ester 
of 5F-NPB-22 (compound 
10, exact m/z for protonated 
molecular ion 279.1503) with 
NCE at 35
Fig. 4  Overlaid extracted ion chromatograms (exact mass ± 2.5 ppm) 
of the major detected PB-22 human liver microsome (HLM)-derived 
metabolites in the presence of ethanol: a = parent drug PB-22; 
b = monohydroxylation; c = carbonylation; d = monohydroxylation 
with N-dealkylation; e = ester hydrolysis (17); f = ester hydrolysis 
with monohydroxylation; g = PB-22 ethyl ester (15); h = PB-22 ethyl 
ester with monohydroxylation
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ester-containing SCs in the presence of ethanol, which gives 
rise to a new family of potential markers for SC and etha-
nol concomitant use. In the case of PB-22 and 5F-PB-22, 
our findings suggested that the ethyl ester formation was 
catalysed by hCES (most likely hCES-1 subtype as in the 
case of cocaine metabolism), because no ethyl ester forma-
tion was observed in the absence of the HLMs, nor when 
CES activity was inhibited (by either nonspecific or specific 
inhibitors). Furthermore, multiple hydroxylated metabolites 
of the ethyl esters were also observed, which may constitute 
additional useful (likely urinary) biomarkers of combined 
SC/ethanol use in toxicological analyses. However, PB-22 
contains a labile ester bond in the structure. Thus, when 
using GC–MS with an elevated temperature in the presence 
of ethanol as solvent, transesterification to produce the ethyl 
ester of PB-22 can be observed [28].
NPB‑22 and 5F‑NPB‑22
As for the two indazoles, NPB-22 produced similar in vitro 
metabolites to 5F-NPB-22. Hydrolysis of the ester linkage 
was the major metabolic pathway for both indazole ana-
logues, NPB-22 and 5F-NPB-22. A series of monohydroxy-
lated ester hydrolysis products were observed. In addition, 
ester hydrolysis followed by oxidative defluorination was 
detected for 5F-NPB-22. Extracted ion chromatograms for 
the metabolites of 5F-NPB-22 from in vitro HLM experi-
ments are presented in Fig. 6 and the proposed metabolic 
pathway of 5F-NPB-22 (without ethanol added) is presented 
in Fig. 7. To the best of our knowledge, this is the first report 
of the in vitro metabolism of 5F-NPB22.
In the presence of ethanol, the ethyl esters of NPB-22 
and 5F-NPB-22 were both detected. Interestingly, a small 
amount of the ethyl ester was observed (approximately 
0.5% of the parent compound by abundance) in the pres-
ence of only buffer and ethanol (i.e., without any HLMs, 
see supplementary material S3.11 and S3.14). Indazole 
SCs clearly display more reactivity towards nucleophilic 
agents than their indole counterparts. Indeed, the NPB-22 
family was more rapidly prone to hydrolysis, methanolysis 
and, therefore, ethanolysis (Fig. 8), even in the absence of 
any biocatalyst.
Incubation of ester hydrolysis products with HLM
To further elucidate the mechanism of formation of the 
newly detected SC ethyl esters, hydrolysed SC esters (com-
pounds 12, 13, 16 and 17) were separately incubated with 
HLMs to monitor any ethyl ester product formation. This 
only yielded hydroxylated metabolites (data not shown). 
Incubation with HLMs and ethanol did not result in the 
formation of ethyl esters (illustrated in supplementary 
material S4). We concluded that the investigated biocata-
lysed reactions were highly dependent on the nature of the 
substrate: SC-ethanol transesterification occurred; how-
ever, esterification of the hydrolysed esters with ethanol 
was not observed. Indeed, hCES is well known to accom-
modate ester, thioester, carbamate, and amide bonds in its 
active site [40–42], suggesting that the hydrolysed esters, 
bearing a free carboxylic acid, are not good substrates for 
this enzyme family.
Fig. 5  Proposed metabolic 
pathway for PB-22, inclusive 
of ethyl ester formation in the 
presence of ethanol. (a–h: refer 
to Fig. 4)
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Biological evaluation of PB‑22, NPB‑22, 5F‑PB‑22, 
5F‑NPB‑22, their ethyl esters and their ester 
hydrolysis products
All parent compounds (PB-22, NPB-22, 5F-PB-22, 
5F-NPB-22) showed a concentration dependent response in 
both the  CB1 and  CB2 receptor activation assays (Fig. 9). 
The  EC50 and Emax values were determined as a measure of 
relative potency and efficacy, respectively (see supplemen-
tary material S5.1). Both the  EC50 and Emax values of PB-22 
Fig. 6  Overlaid extracted ion chromatograms (exact mass ± 2.5 ppm) of 5F-NPB-22 HLM-derived metabolites (without ethanol): a = parent drug 
5F-NPB-22; b = ester hydrolysis (12); c = ester hydrolysis with monohydroxylation; d = ester hydrolysis with oxidative defluorination
Fig. 7  Proposed metabolic 
pathways for 5F-NPB-22 (a–d 
refer to Fig. 6)
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and 5F-PB-22 were in good correspondence with the previ-
ously reported result using the same reporter assays [43].
The ester hydrolysis products and ethyl esters were 
also evaluated at both CB receptors (except the 5F-PB-22 
hydrolysis product as this was not available for analysis, 
but has previously been reported to have no activity at  CB1 
and  CB2 [43]). At  CB1 receptors, hydrolysis resulted in a 
strong reduction of the activity (to < 1% that of JWH-018) 
(Fig. 10a, exact values in supplementary material S5.2). The 
ethyl esters of PB-22 and 5F-PB-22 also showed a strongly 
Fig. 8  Overlaid extracted ion chromatograms (exact mass ± 2.5 ppm) of 5F-NPB-22 in the presence of methanol and ethanol (without HLM); 
a = 5F-NPB-22; b = hydrolysis of 5F NPB-22; c = methanolysis of 5F-NPB-22; d = ethanolysis of 5F-NPB-22
Fig. 9  Concentration-dependent response at  CB1 (a) and  CB2 (b) upon stimulation with different SCs. Data are given as mean receptor activa-
tion (%) ± standard deviation (SD) (n = 5–8), normalised to the Emax of JWH-018
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reduced  CB1 activation (3.2 and 4.2% for the PB-22 and 
5F-PB-22 ethyl esters, respectively). No significant  CB1 
receptor activation was found for the indazole (NPB) deriv-
atives. When compared with the Emax of the parent com-
pounds, the relative activity of the ester hydrolysis products 
did not exceed 0.16%, while that of the ethyl esters did not 
exceed 1.1%.
With respect to  CB2 activity, hydrolysis of the ester in the 
parent compound resulted in a strong reduction of the activ-
ity: only 6%  CB2 receptor activation for the ester hydrolysis 
product of PB-22 was found and an almost complete loss in 
 CB2 receptor activation was found for the ester hydrolysis 
products of NPB-22 and 5F-NPB-22 (Fig. 10b, exact values 
in supplementary material S5.3). For PB-22, the ethyl esters 
resulted in a reduced  CB2 activation compared to the par-
ent compound, although still a 35.5%  CB2 receptor activa-
tion (relative to JWH-018) was found at high concentrations 
(1 µM). The ethyl ester of 5F-PB-22 resulted in a 31.7% 
 CB2 activation. For the ethyl esters of the NPB-derivatives, 
11.7 and 11%  CB2 receptor activation was found. When 
compared to the Emax of the parent compounds, the activity 
of the ester hydrolysis products did not exceed 4.73%, while 
that of the ethyl esters did not exceed 28.6%. Because of the 
limited receptor activation at high concentrations, the contri-
bution of these ethyl esters to the pharmacological profile of 
SCs is expected to be minimal. This is distinct from the  CB1 
and  CB2 receptor activation by the hydroxyl-metabolites of 
(5F)-PB-22 (hydroxy-group on the pentyl side chain), where 
much higher activities (> 100% Emax JWH-018) were found 
[43].
Conclusions
Polydrug use is very common amongst illicit and recrea-
tional drug users. Here, we have shown in vitro evidence of 
the formation of SC-ethyl esters through an hCES-catalysed 
transesterification. Given that there are a number of reports 
which describe fatal and nonfatal cases in which toxico-
logical findings are indicative of combined use of SCs and 
Fig. 10  The maximal effect 
obtained at  CB1 (a) and  CB2 
(b). Bars assigned with an 
asterisk are not significantly 
different from basal levels. Data 
are given as the mean percent-
age CB receptor activation (in 
comparison to the Emax of JWH-
018) ± SD (n = 5–8). EtOH 
ethanol
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ethanol, it is suggested that clinical and forensic laborato-
ries should monitor the potential appearance of the reported 
ethyl esters and/or their hydroxylated metabolites to facili-
tate interpretation of such cases. It is worth mentioning that 
detection of the described ethyl esters may be associated 
with several ester-containing SCs (common metabolites to a 
number of SCs); therefore, their detection should be accom-
panied by the concomitant presence of parent drugs (often 
difficult to be detected in urine) or appropriate metabolites 
that are unique to a certain SC to avoid any ambiguous 
reporting. The elimination profiles are needed to understand 
their potential contribution to toxicity in humans using SCs, 
especially if they prove to have a longer half-life than the 
parent compound. However, the ethics of administration of 
these unlicensed substances to humans makes this difficult, 
and the relevance of animal studies is questionable.
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